By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
RESI Boston, scheduled for September 25-27, 2024, is Life Science Nation (LSN)‘s upcoming hybrid event that promises to be a pivotal platform for early-stage deal-making in the life sciences sector. The conference will be held at the Westin Copley Place Hotel, with in-person activities on September 25, followed by two days of virtual partnering on September 26-27.
RESI (Redefining Early Stage Investments) is designed to connect start-ups and early-stage investors across the domains of drugs, devices, diagnostics, and digital health. This event is particularly valuable for fundraising executives seeking to establish connections with investors and licensing partners.
One of RESI’s key features is its investor panels, which offer attendees insights into the latest industry trends and provide guidance on how to effectively communicate with potential partners. These panels serve a dual purpose:
- They offer valuable industry insights from experienced investors.
- They provide attendees with opportunities to learn about individual investors and potentially schedule on-site meetings.
The conference caters to companies at various funding stages, from those seeking seed capital ($25K – $2M) to those looking for Series B funding ($10M – $50M). RESI Boston is expected to attract over 300 early-stage life science investors and licensing partners, as well as more than 300 early-stage life science companies.
Check out the panel lineup below and be sure to maximize the benefits of attending RESI Boston, by registering early. Early bird rates, offering a $300 discount, are available until Friday, August 2.
|
RESI Boston Investor Panels
(September 25) |
|
|
9:00 ET
|
Partnering With Pharma Panel
Pharma Seeking Early-Stage Assets |
|
10:00
ET |
Angel Investors Panel
Explaining the Process of Engagement |
|
11:00
ET |
Digital Health Panel
Accelerating Technologies to Improve Quality of Care |
|
13:00
ET |
Early-Stage Therapeutics Panel
Bringing the Newest Therapies to the Clinic |
|
14:00
ET |
Diagnostics Panel
Advancements for Personalized Care and Medicine |
|
15:00
ET |
Family Offices Panel
Perspectives on Early-Stage Investments |
|
16:00
ET |
AI in Healthcare Panel
Investing in the Intersection of Science and Technology |
Next Phase Newsletter 
Leave a comment